SAN

86.31

+0.15%↑

MRK1

112.8

+0.8%↑

ARGX

784.2

-2.1%↓

PHIA

23.72

+1.24%↑

ONC.US

331.07

-4.62%↓

SAN

86.31

+0.15%↑

MRK1

112.8

+0.8%↑

ARGX

784.2

-2.1%↓

PHIA

23.72

+1.24%↑

ONC.US

331.07

-4.62%↓

SAN

86.31

+0.15%↑

MRK1

112.8

+0.8%↑

ARGX

784.2

-2.1%↓

PHIA

23.72

+1.24%↑

ONC.US

331.07

-4.62%↓

SAN

86.31

+0.15%↑

MRK1

112.8

+0.8%↑

ARGX

784.2

-2.1%↓

PHIA

23.72

+1.24%↑

ONC.US

331.07

-4.62%↓

SAN

86.31

+0.15%↑

MRK1

112.8

+0.8%↑

ARGX

784.2

-2.1%↓

PHIA

23.72

+1.24%↑

ONC.US

331.07

-4.62%↓

Home・Aandelen Lijst・Pharming Group NV

P
Pharming Group NV

Gesloten

1.462 3.32

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.415

Max

1.48

Belangrijke statistieken
By Trading Economics
Inkomsten	2.9M 7.5M
Verkoop	4.1M 97M
EPS	0.009
Winstmarge	7.758
Werknemers	404

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-43M 954M
Vorige openingsprijs	-1.86
Vorige sluitingsprijs	1.462

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 nov 2025, 22:23 UTC

Acquisities, Fusies, Overnames

BHP Abandons Bid for Anglo American Following New Talks

23 nov 2025, 22:16 UTC

Acquisities, Fusies, Overnames

Macquarie Proposes $7.5 Billion Takeover of Logistics Operator Qube

23 nov 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Macquarie Proposes $7.5B Takeover of Logistics Operator Qube

23 nov 2025, 19:00 UTC

Winsten

Dell, HP Inc., Alibaba, Zoom, Deere, and More Stocks to Watch This Week -- Barrons.com

23 nov 2025, 00:50 UTC

Winsten

Wall Street Goes on a Wild Ride: 'No One Was Expecting This' -- WSJ

22 nov 2025, 10:30 UTC

Winsten

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22 nov 2025, 10:30 UTC

Acquisities, Fusies, Overnames

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22 nov 2025, 09:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 22:42 UTC

Marktinformatie

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 nov 2025, 21:47 UTC

Marktinformatie

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 nov 2025, 21:43 UTC

Marktinformatie

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 nov 2025, 20:18 UTC

Marktinformatie

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 nov 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 nov 2025, 19:48 UTC

Marktinformatie

Precious Metals Fall for the Week -- Market Talk

21 nov 2025, 19:44 UTC

Winsten

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 nov 2025, 19:37 UTC

Marktinformatie

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 nov 2025, 19:27 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

21 nov 2025, 19:27 UTC

Marktinformatie

Winsten

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 nov 2025, 19:20 UTC

Marktinformatie

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 nov 2025, 18:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 nov 2025, 18:37 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 nov 2025, 18:34 UTC

Marktinformatie

Winsten

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 nov 2025, 18:28 UTC

Winsten

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 18:03 UTC

Marktinformatie

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 nov 2025, 17:24 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 nov 2025, 17:24 UTC

Marktinformatie

Intuit Seen on Path to Increase Growth -- Market Talk

21 nov 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 nov 2025, 17:05 UTC

Marktinformatie

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

Peer Vergelijking

Prijswijziging

Pharming Group NV Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pharming Group NV - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.